Bortezomib Therapy Followed by Autologous Stem Cell Transplantation in POEMS Syndrome

Kang, Seok-Hui; Lee, Jong-Yul; Chun, Sang Hoon; Park, Hyung-Wook; Min, Chang‐Ki; Kim, Chun-Choo; Kim, Myungshin; Kim, Yonggoo

doi:10.5045/kjh.2008.43.3.145

Cited by 1 publication

(1 citation statement)

References 15 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 2011, VEGF has become one of the major criteria in the revised POEMS criteria, because VEGF is highly correlated with disease activity [ 1 ]. Moreover, there was a single domestic center study with 3 POEMS syndrome patients, which showed reduction of serum VEGF levels in all patients after bortezomib followed by ASCT [ 30 ]. Unfortunately, VEGF levels and whole body PET scans were not fully evaluated for patients in this study.…”

Section: Discussionmentioning

confidence: 99%

Advanced POEMS syndrome treated with high-dose melphalan followed by autologous blood stem cell transplantation: a single-center experience

et al. 2014

View full text Add to dashboard Cite

BackgroundPOEMS syndrome is a rare paraneoplastic syndrome associated with plasma cell dyscrasia. High-dose chemotherapy followed by autologous stem cell transplantation has shown encouraging efficacy in the treatment of patients with POEMS syndrome. However, there are minimal reports on clinical outcomes after autologous stem cell transplantation for patients with advanced disease and very poor performance status.MethodsWe retrospectively evaluated 9 advanced POEMS syndrome patients, who had an Eastern Cooperative Oncology Group performance status score of 3 or 4, and were treated with high-dose melphalan therapy followed by autologous stem cell transplantation from 2004 to 2011.ResultsEight patients achieved initial hematologic response, 4 of whom had complete responses. At a median follow-up of 44 months (range, 8-94 months), 7 patients were alive, with 3-year overall survival rate of 77.8%. There were no hematologic relapses in the survivors. One patient died of disease progression; the other died of pneumonia despite a hematologic response 3 months after autologous stem cell transplantation. All survivors achieved improvement in general performance status and in clinical response.ConclusionHigh-dose melphalan followed by autologous stem cell transplantation can be considered a valid treatment option even for patients with advanced POEMS syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%